

# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## KAMRON

5<sup>th</sup> November, 2018

### BSE Limited

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

### Sub: Submission of Unaudited Financial Results for the quarter ended on 30<sup>th</sup> September, 2018

We refer to our letter dated 24<sup>th</sup> October, 2018 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30<sup>th</sup> September, 2018.


We are enclosing herewith copy of the said Unaudited Financial Results.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

For KAMRON LABORATORIES LIMITED



KAMLESH J. LASKARI  
MANAGING DIRECTOR



Encl: As above.

**KAMRON LABORATORIES LIMITED**

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaE-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)**KAMRON****STATEMENT OF STANDALONE UNAUDITED RESULTS  
FOR THE QUARTER AND SIX MONTHS ENDED ON 30<sup>TH</sup> SEPTEMBER, 2018**

(Rs. In lakh)

| Particulars         |  | Quarter ended on |             |             | Half Year ended on<br>(Cumulative) |             | Previous<br>Year ended<br>on |
|---------------------|--|------------------|-------------|-------------|------------------------------------|-------------|------------------------------|
|                     |  | 30-09-2018       | 30-06-2018  | 30-09-2017  | 30-09-2018                         | 30-09-2017  | 31-03-2018                   |
| (Refer Notes Below) |  | (Unaudited)      | (Unaudited) | (Unaudited) | (Unaudited)                        | (Unaudited) | (Audited)                    |
| 1                   | Revenue from operations  | 172.18           | 174.02      | 167.45      | 346.20                             | 457.06      | 817.01                       |
| 2                   | Other income   | 1.27             | 0.08        | -           | 1.35                               | 0.24        | 21.47                        |
| 3                   | Total Income (1+2)   | 173.45           | 174.10      | 167.45      | 347.55                             | 457.30      | 838.48                       |
| 4                   | Expenses   |                  |             |             |                                    |             |                              |
|                     | a. Cost of Materials consumed  | 9.27             | 63.14       | 109.72      | 72.41                              | 136.48      | 363.63                       |
|                     | b. Purchases of stock-in-trade   | 45.37            | -           | -           | 45.37                              | 140.30      | 140.30                       |
|                     | c. Changes in inventories of<br>finished goods, work-in-progress<br>and stock-in-trade | 141.04           | (16.50)     | (11.08)     | 124.54                             | (17.75)     | (42.82)                      |
|                     | d. Employee benefits expense   | 45.19            | 42.76       | 37.82       | 87.95                              | 69.54       | 138.97                       |
|                     | e. Finance costs   | 2.43             | 2.97        | 9.51        | 5.40                               | 24.82       | 33.65                        |
|                     | f. Depreciation & amortisation<br>expense  | 18.33            | 18.35       | 1.46        | 36.68                              | 29.26       | 72.91                        |
|                     | g. Other expenses  | 61.29            | 63.22       | 20.2        | 124.51                             | 74.00       | 130.41                       |
|                     | Total Expenses   | 322.92           | 173.94      | 167.63      | 496.87                             | 456.65      | 837.05                       |
| 5                   | Profit / (Loss) before exceptional<br>items and tax (3-4)                              | (149.47)         | 0.16        | (0.18)      | (149.31)                           | 0.65        | 1.43                         |
| 6                   | Exceptional items  |                  | -           | -           | -                                  | -           | -                            |
| 7                   | Profit / (Loss) before tax (5+6)   | (149.47)         | 0.16        | (0.18)      | (149.31)                           | 0.65        | 1.43                         |
| 8                   | Tax expense:   |                  |             |             |                                    |             |                              |
|                     | Current tax  |                  | -           | -           | -                                  | -           | -                            |
|                     | Deferred tax   |                  | -           | -           | -                                  | -           | -                            |
|                     | Earlier Year   |                  |             | -           | -                                  | -           | 1.25                         |
| 9                   | Profit (Loss) for the period from<br>continuing operations (7-8)                       | (149.47)         | 0.16        | (0.18)      | (149.31)                           | 0.65        | 0.18                         |
| 10                  | Profit/(loss) from discontinuing<br>operations before Tax                              |                  | -           | -           | -                                  | -           | -                            |
| 11                  | Tax expense of discontinuing<br>operations   |                  | -           | -           | -                                  | -           | -                            |
| 12                  | Profit/(loss) from Discontinuing<br>operations (after tax) (10-11)                     |                  | -           | -           | -                                  | -           | -                            |
| 13                  | Profit / (Loss) for the period (9+12)  | (149.47)         | 0.16        | (0.18)      | (149.31)                           | 0.65        | 0.18                         |



FOR, KAMRON LABORATORIES LTD.

*Kamrun*  
MANAGING DIRECTOR



**KAMRON LABORATORIES LIMITED**

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaE-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)**KAMRON**

| Particulars |  | Quarter ended on |             |               | Half Year ended on<br>(Cumulative) |             | Previous<br>Year ended<br>on<br>31-03-2018 |
|-------------|--|------------------|-------------|---------------|------------------------------------|-------------|--|
|             |  | 30-09-2018       | 30-06-2018  | 30-09-2017    | 30-09-2018                         | 30-09-2017  |  |
|             |  | (Unaudited)      | (Unaudited) | (Unaudited)   | (Unaudited)                        | (Unaudited) |  |
| 14          | <b>Other Comprehensive Income</b>  |                  | -           | -             |                                    | -           | -  |
|             | <i>Items that will not be reclassified<br/>subsequently to profit or loss</i>      |                  | -           | -             |                                    | -           | -  |
|             | Mention Item.....  |                  |             |               |                                    |             |  |
|             | Mention Item.....  |                  |             |               |                                    |             |  |
|             | Mention Item.....  |                  |             |               |                                    |             |  |
|             | Income tax relating to items that<br>will not be reclassified to profit or<br>loss |                  | -           | -             |                                    | -           | -  |
|             | <i>Items that will be reclassified<br/>subsequently to profit or loss</i>          |                  | -           | -             |                                    | -           | -  |
|             | Mention Item.....  |                  |             |               |                                    |             |  |
|             | Mention Item.....  |                  |             |               |                                    |             |  |
|             | Mention Item.....  |                  |             |               |                                    |             |  |
|             | Income tax relating to items that<br>will be reclassified to profit or loss        |                  | -           | -             |                                    | -           | -  |
|             | <b>Other Comprehensive Income,<br/>net of tax</b>                                  |                  | -           | -             |                                    | -           | -  |
| 15          | <b>Total Comprehensive Income for<br/>the period (13+14)</b>                       | <b>(149.47)</b>  | <b>0.16</b> | <b>(0.18)</b> | <b>(149.31)</b>                    | <b>0.65</b> | <b>0.18</b>                                |
| 16          | Earnings Per Share of Rs. 10 each<br>(for continuing operations)                   |                  |             |               |                                    |             |  |
|             | - Basic  |                  | -           | -             |                                    | 0.01        | -  |
|             | - Diluted  |                  | -           | -             |                                    | 0.01        | -  |
| 17          | Earnings Per Share of Rs. 10 each<br>(for discontinued operations)                 |                  |             |               |                                    |             |  |
|             | - Basic  |                  | -           | -             |                                    | -           | -  |
|             | - Diluted  |                  | -           | -             |                                    | -           | -  |
| 18          | Earnings Per Share of Rs. 10 each<br>(for discontinued & continuing<br>operations) |                  |             |               |                                    |             |  |
|             | - Basic  |                  | -           | -             |                                    | 0.01        | -  |
|             | - Diluted  |                  | -           | -             |                                    | 0.01        | -  |



FOR, KAMRON LABORATORIES LTD.  
*Ganesh J. Gansani*  
 MANAGING DIRECTOR

**KAMRON LABORATORIES LIMITED**

[CIN : L24231GJ1988PLC010956]


Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, IndiaE-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)**KAMRON****STATEMENT OF STANDALONE ASSETS AND LIABILITIES**

(Rs. In lakh)

| Sr.No. | Particulars  | As at 30-09-2018<br>(Unaudited) | As at 31-03-2018<br>(Audited) |
|--------|--|---------------------------------|-------------------------------|
|        | <b>ASSETS</b>  |                                 |                               |
| 1      | <b>Non-Current Assets</b>  |                                 |                               |
|        | Property, plant and equipment  | 1160.37                         | 1187.02                       |
|        | Capital work-in-progress   |                                 | -                             |
|        | Investment property  |                                 | -                             |
|        | Goodwill   |                                 | -                             |
|        | Other intangible Assets  | 47.82                           | 58.45                         |
|        | Intangible Assets under development  |                                 | -                             |
|        | Biological Assets other than bearer plants   |                                 | -                             |
|        | Non-Current Financial Assets:  |                                 |                               |
|        | (i) Investments, Non-Current   |                                 | -                             |
|        | (ii) Trade receivables, Non-Current  |                                 | -                             |
|        | (iii) Loans, Non-Current   | 4.11                            | 5.61                          |
|        | Deferred tax Assets (net)  |                                 | -                             |
|        | Other Non-Current Assets   |                                 | -                             |
|        | <b>Total Non-Current Assets</b>  | <b>1212.31</b>                  | <b>1251.08</b>                |
| 2      | <b>Current Assets</b>  |                                 |                               |
|        | Inventories  | 94.59                           | 229.05                        |
|        | Current financial asset:   |                                 |                               |
|        | (i) Current investments  |                                 | -                             |
|        | (ii) Trade receivables, Current  | 141.36                          | 227.85                        |
|        | (iii) Cash and cash equivalents  | 8.97                            | 13.62                         |
|        | (iv) Bank balance other than above   | 1.78                            | 154.77                        |
|        | (v) Loans, Current   | 7.07                            | 17.09                         |
|        | (vi) Other Current financial Assets  |                                 | -                             |
|        | Current tax Assets (net)   | 0.04                            | -                             |
|        | Other Current Assets   | 426.81                          | 442.31                        |
|        | <b>Total Current Assets</b>  | <b>680.62</b>                   | <b>1084.69</b>                |
| 3      | <b>Non-Current Assets classified as held for sale</b>  |                                 | -                             |
| 4      | <b>Regulatory deferral account debit balances and related deferred tax Assets</b>                |                                 | -                             |
|        | <b>TOTAL ASSETS</b>  | <b>1892.93</b>                  | <b>2335.77</b>                |
|        | <b>EQUITY AND LIABILITIES</b>  |                                 |                               |
| 1      | <b>Equity</b>  |                                 |                               |
|        | Equity share capital   | 585.00                          | 585.00                        |
|        | Other Equity   | (32.81)                         | 117.52                        |
|        | <b>Total Equity</b>  | <b>552.19</b>                   | <b>702.52</b>                 |
| 2      | <b>Liabilities</b>   |                                 |                               |
|        | <b>Non-Current Liabilities</b>   |                                 |                               |
|        | Non-Current financial Liabilities:   |                                 |                               |
|        | (i) Borrowings, Non-Current  |                                 | 376.77                        |
|        | (ii) Trade payables, Non-Current   |                                 | -                             |
|        | (iii) Other Non-Current financial Liabilities  |                                 | -                             |
|        | Provisions, Non-Current  | 20.19                           | 24.40                         |
|        | Deferred tax Liabilities (net)   | 4.58                            | 4.59                          |
|        | Other Non-Current Liabilities  |                                 | -                             |
|        | <b>Total Non-Current Liabilities</b>   | <b>24.78</b>                    | <b>405.76</b>                 |
|        | <b>Current Liabilities</b>   |                                 |                               |
|        | Current financial Liabilities:   |                                 |                               |
|        | (i) Borrowings, Current  | 624.53                          | 755.05                        |
|        | (ii) Trade payables, Current   | 100.14                          | 80.39                         |
|        | (iii) Other Current financial Liabilities  |                                 | -                             |
|        | Other Current Liabilities  | 590.88                          | 391.65                        |
|        | Provisions, Current  | 0.40                            | 0.40                          |
|        | Current tax Liabilities (Net)  |                                 | -                             |
|        | <b>Total Current Liabilities</b>   | <b>1315.95</b>                  | <b>1227.49</b>                |
| 3      | <b>Liabilities directly associated with Assets in disposal group classified as held for sale</b> |                                 | -                             |
| 4      | <b>Regulatory deferral account credit balances and related deferred tax liability</b>            |                                 | -                             |
|        | <b>Total Liabilities</b>   | <b>1340.74</b>                  | <b>1633.25</b>                |
|        | <b>TOTAL EQUITY AND LIABILITIES</b>  | <b>1892.93</b>                  | <b>2335.77</b>                |



FOR, KAMRON LABORATORIES LTD.


  
**MANAGING DIRECTOR**



# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## KAMRON

### Notes:

|   |  |
|---|--|
| 1 | The Company is operating only in one segment i.e. Pharma. Hence segment reporting is not given.  |
| 2 | The Company does not have any subsidiary / associate.  |
| 3 | Provision for taxation/deferred taxation, if any, will be made at the year end.  |
| 4 | Figures, wherever required, are regrouped / rearranged.  |
| 5 | The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 5 <sup>th</sup> November, 2018. |

For KAMRON LABORATORIES LIMITED

*Kamlesh J. Laskari*

**KAMLESH J. LASKARI**  
**MANAGING DIRECTOR**

Date: 5<sup>th</sup> November, 2018.  
Place: Ahmedabad



# KAMRON LABORATORIES LIMITED

[CIN : L24231GJ1988PLC010956]

Regd. Office: Office No. 904, 9<sup>th</sup> Floor, Shapath-I Complex, Opp. Rajpath Club, Nr. Madhur Hotel,  
S. G. Highway, Bodakdev, Ahmedabad – 380 054, Gujarat, India

E-mail : [info@kamronlabs.com](mailto:info@kamronlabs.com)



## KAMRON

5<sup>th</sup> November, 2018

### BSE Limited

Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

**Sub: Submission of Limited Review Report for Financial Results  
for the quarter ended on 30<sup>th</sup> September, 2018**

We refer to our letter dated 5<sup>th</sup> November, 2018 enclosing Unaudited Financial Results for the quarter ended on 30<sup>th</sup> September, 2018.

We are now enclosing herewith Limited Review Report dated 5<sup>th</sup> November, 2018 for Unaudited Financial Results for the quarter ended on 30<sup>th</sup> September, 2018.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

Thanking you,

Yours faithfully,

for KAMRON LABORATORIES LIMITED

*Kamlesh J. Laskari*

KAMLESH J. LASKARI  
MANAGING DIRECTOR



Encl: As above.



## LIMITED REVIEW REPORT

### Review Report to the Board of Directors of Kamron Laboratories Ltd.

We have reviewed the accompanying statement of unaudited financial results of Kamron Laboratories Ltd. ("the Company") for the half year ending 30 September, 2018 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We have reviewed the financial results and other financial information for the half year ended 30 september, 2018 which have been presented solely based on the financial information compiled by the Management.



For **RANGWALA & CO**  
Chartered Accountants  
(Firm's Registration No. 115833W)

  
(Z.E. RANGWALA)

Partner  
(Membership No. 031268)

Place of signature: AHMEDABAD  
Date: 5th November, 2018.